Literature DB >> 10928980

Characterization of the effects of cannabinoids on guinea-pig tracheal smooth muscle tone: role in the modulation of acetylcholine release from parasympathetic nerves.

L Spicuzza1, E B Haddad, M Birrell, A Ling, D Clarke, P Venkatesan, P J Barnes, M G Belvisi.   

Abstract

We investigated the ability of the cannabinoid agonists CP55,940 (CB(1)/CB(2)) and anandamide (endogenous cannabinoid) to modulate electrical field stimulation (EFS)-induced acetylcholine (ACh) release from parasympathetic nerve terminals innervating guinea-pig trachea. We assessed whether modulation of transmitter release translated to an impact on functional responses by investigating the effect of these agents on contractile responses evoked by EFS and ACh. Furthermore, we evaluated the ability of these compounds to elicit bronchodilation in pre-contracted guinea-pig tracheal strips. CP55,940 and anandamide significantly inhibited EFS-evoked ACh release (maximal inhibition of 35.1+/-2.9% and 33.4+/-6.4% at 1 microM, P<0.05, respectively). The CB(1) receptor antagonist SR 141716A (1 microM), had no effect on ACh release and failed to reverse the inhibitory effect of CP55,940 (1 microM). Paradoxically, CP55,940 had no significant effect on EFS-evoked cholinergic contractile responses. Furthermore, CP55,940 did not relax pre-contracted tracheal strips or affect contractile responses to exogenous ACh. This lack of activity on smooth muscle tone is consistent with the fact that no detectable specific binding of [(3)H] CP55,940 was found in tracheal homogenates. These data suggest that cannabinoid agonists inhibit ACh release from cholinergic nerve terminals via activation of CB(2) receptors but that this inhibitory action does not impact on functional responses such as cholinergic contraction.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10928980      PMCID: PMC1572241          DOI: 10.1038/sj.bjp.0703497

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  35 in total

Review 1.  Pharmacology of cannabinoid receptors.

Authors:  A C Howlett
Journal:  Annu Rev Pharmacol Toxicol       Date:  1995       Impact factor: 13.820

2.  Examination of the effect of the cannabinoid receptor agonist, CP 55,940, on electrically evoked transmitter release from rat brain slices.

Authors:  A N Gifford; L Samiian; S J Gatley; C R Ashby
Journal:  Eur J Pharmacol       Date:  1997-04-18       Impact factor: 4.432

3.  Expression of central and peripheral cannabinoid receptors in human immune tissues and leukocyte subpopulations.

Authors:  S Galiègue; S Mary; J Marchand; D Dussossoy; D Carrière; P Carayon; M Bouaboula; D Shire; G Le Fur; P Casellas
Journal:  Eur J Biochem       Date:  1995-08-15

4.  Biochemical and pharmacological characterisation of SR141716A, the first potent and selective brain cannabinoid receptor antagonist.

Authors:  M Rinaldi-Carmona; F Barth; M Héaulme; R Alonso; D Shire; C Congy; P Soubrié; J C Brelière; G Le Fur
Journal:  Life Sci       Date:  1995       Impact factor: 5.037

5.  Characterization of two cloned human CB1 cannabinoid receptor isoforms.

Authors:  M Rinaldi-Carmona; B Calandra; D Shire; M Bouaboula; D Oustric; F Barth; P Casellas; P Ferrara; G Le Fur
Journal:  J Pharmacol Exp Ther       Date:  1996-08       Impact factor: 4.030

6.  Inhibition of exocytotic noradrenaline release by presynaptic cannabinoid CB1 receptors on peripheral sympathetic nerves.

Authors:  E J Ishac; L Jiang; K D Lake; K Varga; M E Abood; G Kunos
Journal:  Br J Pharmacol       Date:  1996-08       Impact factor: 8.739

7.  Further evidence for the presence of cannabinoid CB1 receptors in guinea-pig small intestine.

Authors:  R G Pertwee; S R Fernando; J E Nash; A A Coutts
Journal:  Br J Pharmacol       Date:  1996-08       Impact factor: 8.739

8.  Electrically evoked acetylcholine release from hippocampal slices is inhibited by the cannabinoid receptor agonist, WIN 55212-2, and is potentiated by the cannabinoid antagonist, SR 141716A.

Authors:  A N Gifford; C R Ashby
Journal:  J Pharmacol Exp Ther       Date:  1996-06       Impact factor: 4.030

9.  Paradoxical facilitation of acetylcholine release from parasympathetic nerves innervating guinea-pig trachea by isoprenaline.

Authors:  M G Belvisi; H J Patel; T Takahashi; P J Barnes; M A Giembycz
Journal:  Br J Pharmacol       Date:  1996-04       Impact factor: 8.739

10.  Comparison of the pharmacology and signal transduction of the human cannabinoid CB1 and CB2 receptors.

Authors:  C C Felder; K E Joyce; E M Briley; J Mansouri; K Mackie; O Blond; Y Lai; A L Ma; R L Mitchell
Journal:  Mol Pharmacol       Date:  1995-09       Impact factor: 4.436

View more
  6 in total

1.  The endogenous cannabinoid agonist, anandamide stimulates sensory nerves in guinea-pig airways.

Authors:  R C Tucker; M Kagaya; C P Page; D Spina
Journal:  Br J Pharmacol       Date:  2001-03       Impact factor: 8.739

Review 2.  The endocannabinoid system as an emerging target of pharmacotherapy.

Authors:  Pál Pacher; Sándor Bátkai; George Kunos
Journal:  Pharmacol Rev       Date:  2006-09       Impact factor: 25.468

3.  Cannabinoids inhibit cholinergic contraction in human airways through prejunctional CB1 receptors.

Authors:  S Grassin-Delyle; E Naline; A Buenestado; C Faisy; J-C Alvarez; H Salvator; C Abrial; C Advenier; L Zemoura; P Devillier
Journal:  Br J Pharmacol       Date:  2014-06       Impact factor: 8.739

4.  Cannabinoid 1 (CB1) receptors coupled to cholinergic motorneurones inhibit neurogenic circular muscle contractility in the human colon.

Authors:  Nicholas M Hinds; Katja Ullrich; Scott D Smid
Journal:  Br J Pharmacol       Date:  2006-05       Impact factor: 8.739

Review 5.  Airway hypersecretion in allergic rhinitis and asthma: new pharmacotherapy.

Authors:  Duncan F Rogers
Journal:  Curr Allergy Asthma Rep       Date:  2003-05       Impact factor: 4.919

Review 6.  Endocannabinoid System in the Airways.

Authors:  Turgut Emrah Bozkurt
Journal:  Molecules       Date:  2019-12-17       Impact factor: 4.411

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.